.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,894,051

« Back to Dashboard
Patent 6,894,051 protects GLEEVEC and is included in two NDAs. There have been two Paragraph IV challenges on Gleevec.

Protection for GLEEVEC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-six patent family members in thirty-one countries.

Summary for Patent: 6,894,051

Title: Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Abstract:The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]benzamide of formula 1, which may be used for example for tumor therapy.
Inventor(s): Zimmermann; Jurg (Basel, CH), Sutter; Bertrand (Hesingue, FR), Burger; Hans Michael (Allschwil, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:09/463,097
Patent Claim Types:
see list of patent claims
Compound; Composition; Process; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 5th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
GLEEVEC
imatinib mesylate
CAPSULE;ORAL021335-001May 10, 2001DISCNNo6,894,051*PED► subscribeY
Novartis
GLEEVEC
imatinib mesylate
CAPSULE;ORAL021335-002May 10, 2001DISCNNo6,894,051*PED► subscribeY
Novartis
GLEEVEC
imatinib mesylate
TABLET;ORAL021588-001Apr 18, 2003RXNo6,894,051*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,894,051

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1764/97Jul 18, 1997
PCT Information
PCT FiledJuly 16, 1998PCT Application Number:PCT/EP98/04427
PCT Publication Date:January 28, 1999PCT Publication Number: WO99/03854

Non-Orange Book Patents for Patent: 6,894,051

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE43932Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use► subscribe
7,151,106Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use► subscribe
7,544,799Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,894,051

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina016351► subscribe
Argentina043266► subscribe
Austria251152► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc